Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0BR8X
|
|||
| Drug Name |
PUL-042
|
|||
| Synonyms |
ODN-M362/Pam2CSK4; Pam2-ODN; Pam2/ODN; Pam2CSK4/ODN-M362; PUL-042
Click to Show/Hide
|
|||
| Drug Type |
Protein/peptide drug
|
|||
| Indication | Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 2 | [1] | |
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL
|
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN toll-like receptor 2 (TLR2) | Target Info | Agonist | [2], [3] |
| HUMAN toll-like receptor 6 (TLR6) | Target Info | Agonist | [2], [3] | |
| HUMAN toll-like receptor 9 (TLR9) | Target Info | Agonist | [2], [3] | |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04312997) The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection. U.S. National Institutes of Health. | |||
| REF 2 | Pulmotects lead product, PUL-042, is a clinical stage inhaled therapeutic that in preclinical studies stimulates the innate immune system in minutes to provide immediate and effective protection against all major classes of pathogens that lasts for days. | |||
| REF 3 | TLR 2/6/9 agonist PUL-042 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.